BOSTON and SYDNEY — 16 May 2018 — GI Dynamics®, Inc. (ASX: GID) (the Company) will hold its 2018 Annual Meeting of Stockholders on 24 May 2018 at 6:00 pm United States Eastern Daylight Time, (which is 25 May 2018 at 8:00 am Australian Eastern Standard Time), at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111.
Immediately following the Annual Meeting of Stockholders, Company management will provide a corporate update.
If not attending in person, the meeting and corporate update can be accessed through a teleconference line.
Accessing the Annual Meeting of Stockholders and Corporate Update via the teleconference line:
Please dial-in five minutes prior to the start of the call. Regional dial-in numbers are as follows:
United States (Toll-Free): 877 407 6184
Australia (Toll-Free): 1 800 687 004
United Kingdom (Toll-Free): 0 800 756 3429
Germany (Toll-Free): 0 800 182 0040
Germany (Dial-in via Mobile Phone): 0 800 184 4713
Switzerland (Toll Free): 800 835 525
Switzerland (Dial-in via Mobile Phone): 800 891 374
For all other regions or if you are unable to access the call through any of the above numbers please dial the toll number as follows:
International (Toll; charges will apply): 201 389 0877
The transcript and audio recording will be available on the company’s website shortly following the call.
About GI Dynamics
GI Dynamics®, Inc. (ASX:GID) is the developer of EndoBarrier, the first endoscopically-delivered device therapy for the treatment of type 2 diabetes and obesity. EndoBarrier is not approved for sale and is limited by federal law to investigational use only. Founded in 2003, GI Dynamics is headquartered in Boston, Massachusetts. For more information please visit www.gidynamics.com.
This announcement may contain forward-looking statements. These forward-looking statements are based on GI Dynamics management’s current estimates and expectations of future events as of the date of this announcement. Furthermore, the estimates are subject to several risks and uncertainties that could cause actual results to differ materially and adversely from those indicated in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with our ability to continue to operate as a going concern, our ability to maintain compliance with our obligations under the Convertible Loan Note executed with Crystal Amber Fund Limited, obtaining and maintaining regulatory approvals required to market and sell our products; obtaining funding from third parties; the consequences of stopping the ENDO trial and the possibility that future clinical trials will not be successful or confirm earlier results; the timing and costs of clinical trials; the timing of regulatory submissions; the timing, receipt and maintenance of regulatory approvals; the timing and amount of other expenses; the timing and extent of third-party reimbursement; intellectual-property risk; risks related to excess inventory; and risks related to assumptions regarding the size of the available market, the benefits of our products, product pricing, timing of product launches, future financial results and other factors, including those described in our filings with the U.S. Securities and Exchange Commission. Given these uncertainties, one should not place undue reliance on these forward-looking statements. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events or otherwise, unless we are required to do so by law.